Quotables
"To place a man in a multi-stage rocket and project him into the controlling gravitational field of the moon where the passengers can make scientific observations, perhaps land alive, and then return to earth--all that constitutes a wild dream worthy of Jules Verne. I am bold enough to say that such a man-made voyage will never occur regardless of all future advances."
Lee deForest, American radio pioneer ; 1957
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7029671 | Method for activating human antigen-presenting cells, activated human antigen-presenting cells, and use thereof The invention relates to a method for activating human-derived antigen-presenting cells by in vitro cultivation with at least one of the glycoside compounds represented by formula (A) or salts thereof [preferred example: (2S,3S,4R)-1-(α-D-galactopyranosyloxy)-2-hex... | 04/18/2006 |
| 6977248 | Pharmaceutical preparations for the inhibition of herpes simplex virus 1 entry Disclosed herein are polysaccharide preparations enriched in 3-OST-3 modified heparan sulfate. Also disclosed are methods of treating herpes simplex viral type-1 infection using the pharmaceutical preparations of the invention. ... | 12/20/2005 |
| 6967242 | Antimicrobial 2-deoxystreptamine compounds The present invention is directed to analogs of aminoglycoside compounds of the class having a glycosylated 2-deoxystreptamine (2-DOS) ring as well as their preparation and use as prophylactic or therapeutics against microbial infection. Compounds of the invention c... | 11/22/2005 |
| 6960344 | Use of imine-forming polysaccharides as adjuvants and immunostimulants The present invention relates to polysaccharide conjugates that comprise: a polysaccharide that binds to surface-receptors present on Antigen Presenting Cells, conjugated to one or more compounds having stable carbonyl groups covalently attached, either directly or ... | 11/01/2005 |
| 6930180 | Chemically modified proteins with a carbohydrate moiety The present invention relates to a chemically modified mutant protein including a cysteine residue substituted for a residue other than cysteine in a precursor protein, the substituted cysteine residue being subsequently modified by reacting the cysteine residue wit... | 08/16/2005 |
| 6930200 | Multicomponent synthesis of amino acids and derivatives thereof Mono-substituted and di-substituted alpha-amino acids and derivatives thereof, substituted at the alpha positon with one (mono-) or two (di-) substituents (R2 and/or R3) as shown in Formula 1: N(R4R5)C(R2R3... | 08/16/2005 |
| 6927210 | Ectoparasiticidal aqueous suspension formulations of spinosyns The invention provides a stable ectoparasiticidal aqueous suspension formulation of a spinosyn, comprising the spinosyn, or a physiologically acceptable derivative or salt thereof, milled to an average particle size of 1 to 15 microns, a surfactant in an amount effe... | 08/09/2005 |
| 6924308 | Therapeutic process for inhibiting NF-κB A therapeutic process is provided for the inhibition of NF-κB in mammals in whose cells NF-κB has been activated by an agency external to said cell. ... | 08/02/2005 |
| 6921811 | Bioactive coating composition and methods The present invention provides a bioactive coating composition, method and devices for bodily fluid-contacting surfaces. The coating comprises a complex of Formula II: wherein R1 is an C1-18alkyl or C6-32aryl group, each R2 | 07/26/2005 |
| 6916796 | Use of pullulan as a slowly digested carbohydrate The present invention is directed to the use of pullulan as a slowly digested carbohydrate and to its incorporation into food products, especially beverages and meal replacement products. ... | 07/12/2005 |
| 6908907 | Prevention and treatment of tumor growth, metastasis, and thromboembolic complications in cancer patients This invention provides for the prevention and treatment of tumor growth, metastasis, and cancer-mediated thrombosis through the administration, in combination, of a short or long acting GPIIb/IIIa antagonist (A) and anticoagulant (B) that might include the followin... | 06/21/2005 |
| RE38743 | Mixtures of particular LMW heparinic polysaccharides for the prophylaxis/treatment of acute thrombotic events Heterogeneous intimate admixtures of sulfated heparinic polysaccharides, well suited for the prophylaxis/treatment of acute thrombotic episodes in a human patient, comprise immixture of sulfated polysaccharides having a weight average molecular weight less than that... | 06/14/2005 |
| 6900189 | Analgesic and glucosamine compositions This invention relates to a composition comprising a glucosamine material and an analgesic compound such as a nonsteroidal anti-inflammatory drug (NSAID) and/or an opioid analgesic and its use for treatment of pain in pharmaceutical or veterinary applications. When ... | 05/31/2005 |
| 6897198 | Method of treatment with combinations of statin and aryl-substituted propanolamine derivatives Substituted propanolamine derivatives, their pharmaceutically tolerated salts and physiologically functional derivatives thereof are described. Also described are compounds of formula I in which the radicals hav... | 05/24/2005 |
| 6894034 | Sebum production inhibitors Sebum production inhibitors containing as an active ingredient a compound of general formula (1) below having a glucuronic acid derivative and a glucosamine derivative in the structure or a pharmacologically acceptable salt thereof | 05/17/2005 |
| 6881726 | Aqueous compositions containing metronidazole An aqueous solution of metronidazole in which the concentration of metronidazole is higher than 0.75%. The solution contains a combination of solubility-enhancing agents, one of which is a cyclodextrin such as beta-cyclodextrin and the second is a compound other tha... | 04/19/2005 |
| 6881837 | Chemical synthesis of S-adenosyl-L-methionine with enrichment of (S,S)-isomer This invention relates to the production of S-adenosyl-L-methionine by means of a chemical process wherein enrichment of the bioactive (S,S)-isomer is achieved. The process is simple, efficient, economical and reproducible on large scale. ... | 04/19/2005 |
| 6875753 | Methods for cell mobilization using in vivo treatment with hyaluronan (HA) The use of forms of hyaluronic acid having a molecular weight less than about 750,000 daltons selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof is provided for the same purposes known for using recombinant GM-CSF or ... | 04/05/2005 |
| 6869939 | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin The present invention provides aqueous parenteral formulations containing an antiarrhythmic agent, such as amiodarone, and a sulfoalkyl ether cyclodextrin. The liquid formulations are clear, sterilizable, and chemically and physically stable. The liquid formulations... | 03/22/2005 |
| 6864063 | Use of modified starch as an agent for forming a thermoreversible gel The invention relates to the use of modified starch obtainable by treating amylose containing starch in aqueous medium with an enzyme from the group of the α-1,4-α-1,4-glucosyl transferases (EC 2.4.1.25) or an enzyme the activity of which corresponds to that of en... | 03/08/2005 |
| 6852701 | Anticonvulsant derivatives useful for preventing the development of Type II diabetes mellitus and Syndrome X Anticonvulsant derivatives useful for preventing the development of Type II diabetes mellitus and Syndrome X are disclosed. ... | 02/08/2005 |
| 6841543 | Methods of inhibiting production of T helper type 2 cytokines in human immune cells Methods for modulating immune responses are provided. The methods involve contacting an immune cell with an agent that modulates interaction of a compound comprising a Lewis antigen with the immune cell such that production by the immune cell of at least one cytokin... | 01/11/2005 |
| 6833363 | N-sulphated hyaluronic acid compounds, derivatives thereof and a process for their preparation The present invention is directed to novel sulphated compounds of hyaluronic acid and derivatives thereof, optionally salified, wherein the glucosamines are partially N-sulphated and partially or totally O-sulphated in position 6. The compounds of the invention have... | 12/21/2004 |
| 6828311 | Formulation for the parenteral application of a sodium channel blocker The invention relates to a new formulation containing Bill 890 or one of the pharmaceutically acceptable salts thereof for parenteral administration. ... | 12/07/2004 |
| 6828307 | Low molecular weight sulphated polysaccharide to obtain a medicine with antithrombotic activity The invention concerns the use of a sulphated polysaccharide capable of being obtained by radical depolymerization of a raw fucan derived from Pheophyceae, said polysaccharide having a molar mass not more than 10,000 g/mol, to obtain a medicine for preventing or tre... | 12/07/2004 |
| 6800613 | Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ mono- and disaccharide-based compounds for selectively stimulating immune responses i... | 10/05/2004 |
| 6790840 | Reversibly cross-linked hydrogels A hydrogel composition and methods of preparing and using the same are disclosed. The hydrogel composition comprises an oxidized polysaccharide, and a cross-linker having at least two functional cross-linking groups. The cross-linker reversibly cross-links the polys... | 09/14/2004 |
| 6770672 | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof The present invention provides an antiproliferative compound having the structural formula wherein X is oxygen, nitrogen or sulfur; Y is selected from the group consisting of oxygen, nitrogen and sulfur wherein when Y is... | 08/03/2004 |
| 6765109 | Preparation of S-aryl-cysteine and its derivatives The present invention provides a method for preparing S-aryl cysteine. Specifically, the present invention provides enantioselective method for preparing S-aryl cysteine starting from cystine, cysteine or serine amino acid. The methods of the present invention provi... | 07/20/2004 |
| 6762282 | High yield S-nitrosylation process A method for producing a S-nitrosylated species is provided. The method comprises: (a) providing a deoxygenated, alkaline aqueous solution comprising a thiol and a nitrite-bearing species; (b) acidifying the solution by adding acid to the solution while concurrently... | 07/13/2004 |
| 6759523 | Antimicrobial 2-deoxystreptamine compounds The present invention is directed to analogs of aminoglycoside compounds of the class having a glycosylated 2-deoxystreptamine (2-DOS) ring as well as their preparation and use as prophylactic or therapeutics against microbial infection. Compounds of the invention c... | 07/06/2004 |
| 6756489 | Substituted tetrahydropyrane derivatives, method for producing same, their use as medicine or diagnostic agent, as well as medicine containing same Substituted tetrahydropyran derivatives, processes for their preparation, their use as a pharmaceutical or diagnostic, and pharmaceutical comprising them. The invention relates to compounds of the formula I in which the ... | 06/29/2004 |
| 6753346 | CETP activity inhibitor The present invention provides a CETP activity inhibitor comprising as an active ingredient a compound represented by the formula (I): wherein R represents a straight chain or branched alkyl group; a straight chain or br... | 06/22/2004 |
| 6743784 | Estrogen mimetics lacking reproductive tract effects A method for treating symptoms, diseases and conditions in extra-reproductive tract tissues that are responsive to treatment with estrogen, using triarylethanes of formula (I) wherein R1 is —O(CH2... | 06/01/2004 |
| 6730664 | Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins A pharmaceutical formulation which comprises a parenterally acceptable carrier or diluent, estramustine phosphate and a sulfoalkyl ether cyclodextrin. The formulation can be administered according to a combined chemotherapy regimen in association with one or more ch... | 05/04/2004 |
| 6723709 | Biomaterials for preventing post-surgical adhesions comprised of hyaluronic acid derivatives New biomaterials essentially constituted by esterified derivatives of hyaluronic acid or by cross-linked derivatives of hyaluronic acid for use in the surgical sector, particularly for use in the prevention of post-surgical adhesion. ... | 04/20/2004 |
| 6723704 | Sphingoglycolipid A glycosphingolipid having a sugar chain containing α-glucosamine and β-glucosamine is disclosed. Such glycosphingolipid is advantageous in that possibly being manufactured in a facile and inexpensive manner, and that exhibiting moisturizing effect and immuno-enha... | 04/20/2004 |
| 6716970 | Water soluble, randomly substituted partial N-partial O-acetylated chitosan, preserving compositions containing chitosan, and processes for making thereof The present invention is directed to a water soluble, randomly substituted partial N-, partial O-acetylated chitosans or chitosan derivatives and methods of preparing water soluble, randomly substituted partial N-, partial O-acetylated chitosans or chitosan derivati... | 04/06/2004 |
| 6713459 | Methods for the prophylactic and therapeutic treatment of cardiac tissue damage The invention provides a method for treating tissue damage caused by ischemia/reperfusion, microbial infection, or sepsis using (1→3)-β-D-glucans to modulate immune response mediators and their effects. ... | 03/30/2004 |
| 6713454 | Prodrugs of etoposide and etoposide analogs The present invention provides amphiphilic prodrugs comprising a therapeutic compound conjugated to an PEG-oligomer/polymer and methods for using said prodrugs to enable oral drug delivery and/or delivery of drugs across the blood brain barrier into the central nerv... | 03/30/2004 |
